Oncology | Blood cancer

Your partner in oncohematology

QIAGEN’s oncohematology solutions bring innovation in molecular testing, faster and without compromise. We support your clinical cancer care and advancements in molecular research with a comprehensive assay, platform and service portfolio – from Sample to Insight.

Contact an expert

Discover how QIAGEN can help you.

Get in touch

Sensitive JAK2 V617F mutation detection using real-time PCR

The ipsogen JAK2 RGQ PCR Kit is the only FDA-cleared kit for detection of the JAK2 V617F/G1849T allele, a World Health Organization (WHO) diagnostic criterion for myeloproliferative neoplasms (MPNs) (1).

Discover the test

Your partner for blood cancer companion diagnostics

Successful companion diagnostic (CDx) and drug co approval requires the right partner. QIAGEN has a proven track record in IVD development, global regulatory capabilities and global commercialization expertise.

Learn more

Your partner for blood cancer companion diagnostics

ipsogen real-time PCR blood cancer assays

Test with confidence

QIAGEN's extensive oncohematology portfolio includes multiple solutions for highly sensitive and accurate leukemia biomarker detection and/or quantification. Test with ipsogen, for results you can trust.

See products

Maximize your blood cancer clinical research

CALR

Reliable and sensitive detection of CALR exon 9 mutations (c.1091_1162 region) and identification of Types 1 & 2, in a single real-time PCR run to optimize your time and workflow

See how

MPL

Sensitive and reliable detection of the MPL W515L and MPL W515K mutations

Discover more

BCR-ABL1 Mbcr

Highly sensitive and reliable quantification of IS-standardized BCR-ABL1 Mbcr molecular response

Learn more

BCR-ABL1 mbcr

Sensitive quantification of BCR-ABL1 mbcr for monitoring studies

PML-RARA

Sensitive quantification of PML-RARA bcr1, bcr2 and bcr3 separately for monitoring studies

NPM1

Identification of NPM1 mutations type A, B, and D, followed by specific quantification of each of these NPM1 mutations for monitoring studies

Explore the power of one

Maximize the information derived from a single total nucleic acid sample by simultaneously preparing DNA and RNA libraries in one consolidated workflow. With the new QIAseq Multimodal Leukemia Panel, you can simultaneously detect RNA fusions, exon skipping events and gene expression levels, along with SNVs, InDels, CNVs profiles, in a single, one-day workflow from as little as 10 ng of sample.

Explore now

Easily classify myeloid malignancies

QIAGEN Digital Insights clinical decision support software enables faster test turnaround times and higher confidence reporting for many indications on your sequencing platform. QIAGEN Clinical Insight (QCI) Interpret provides transparent automation of blood cancer sub-classification and prognostic assessment, showing you how certain cancer subtypes potentially relate to therapeutic options.

See the software

References

1. Arber, D.A. et al. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391-2405.

ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; CNV: Copy number variation; InDel: Inserstions/deletions; IS: International Scale; MPN: Myeloproliferative neoplasms; MRD: Minimal residual disease; NGS: Next-generation sequencing; Ph: Philadelphia chromosome; SNV: Single nucleotide variation.

The ipsogen JAK2 RGQ PCR Kit is intended for in vitro diagnostic use.

The CALR RGQ PCR Kit, ipsogen MPL W515L/K MutaScreen Kit , BCR-ABL1 Mbcr RGQ RT-PCR Kit, ipsogen BCR-ABL1 mbcr Kit, ipsogen PML-RARA kits, ipsogen NPM1 MutaScreen Kit and ipsogen NPM1 MutaQuant kits are for Research Use Only. Not for use in diagnostics procedures. No claim or representation is intended to provide information for the diagnosis, prevention, or treatment of a disease.

QIAseq Panels are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.

QCI Interpret is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic next-generation sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases, annotations, drug labels, and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is NOT intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national, and local clinical laboratory regulations and other specific accreditations requirements.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor.